QQ客服 官方微博 反馈留言

	RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody.
	Hu, S.a,b,c; Dai, H.d; Zhang, T.a,c; Fu, W.b,c; Berezov, S.D.c; Chen, C.e; Jorissen, D.f; Takeda, H.f; Bethune, A.N.a,c,f
刊名	Cancer Letters (CANCER LETT)
	2015
卷号	Vol.357 No.1页码:374-383
ISSN号	0304-3835
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2929302
专题	天津大学
作者单位	1.aTranslational Medicine Research Institute and International Joint Cancer Institute, The Second Military Medical University, Shanghai, 200433, China 2.bCancer Center, PLA General Hospital, PLA Postgraduate School of Medicine, 28 Fuxing Road, Beijing, 100853, China 3.cAsian-Pacific Biosignatures Center, Tianjin Joint Academy of Biomedicine and Technology, Tianjin, 300457, China 4.dDepartment of Anesthesiology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, 210002, China 5.eSchool of Life Sciences, Tianjin University, Tianjin, 300072, China 6.fMolecular Drug Discovery Center, Xi'an Jinwa Pharmaceutical Co, Ltd, Xi'an, Shaanxi, 710000, China
推荐引用方式 GB/T 7714	Hu, S.a,b,c,Dai, H.d,Zhang, T.a,c,et al. RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody.[J]. Cancer Letters (CANCER LETT),2015,Vol.357 No.1:374-383.
APA	Hu, S.a,b,c.,Dai, H.d.,Zhang, T.a,c.,Fu, W.b,c.,Berezov, S.D.c.,...&Bethune, A.N.a,c,f.(2015).RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody..Cancer Letters (CANCER LETT),Vol.357 No.1,374-383.
MLA	Hu, S.a,b,c,et al."RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody.".Cancer Letters (CANCER LETT) Vol.357 No.1(2015):374-383.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。